Clinical Trial Update: Indirect Comparison of Tobramycin Solution for Inhalation Versus Aztreonam Lysine for Inhalation in the Treatment of Cystic Fibrosis

View source ↗

Summary

Clinical trial update comparing inhaled tobramycin versus inhaled aztreonam for cystic fibrosis using indirect comparison.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Cayston (aztreonam lysine)
• TOBI (Tobramycin inhalation solution)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cystic Fibrosis | Status: COMPLETED